阿里皮普拉或布普罗增量与在治疗耐药抑郁症中切换到布普罗:风险效益分析
William U Meyerson1,2,3, Eric L Ross4, Chris J Kennedy1,2,5
1Center for Precision Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.
The Journal of clinical psychiatry
|September 26, 2025
概括
组合布洛 (C-BUP) 对抗性抑郁症的治疗结果比切换 (S-BUP) 或阿里皮普拉 (A-ARI) 更好,特别是在85.5岁以下的成年人中. C-BUP提供了有效性和耐受性的有利平衡,为临床决策提供了信息.
科学领域:
- 精神病学和心理健康 精神病学和心理健康
- 药物经济学 药物经济学
- 临床决策分析 临床决策分析
背景情况:
- 耐治疗抑郁症 (TRD) 带来了重大挑战,需要有效的增强疗法或组合疗法.
- 阿里皮普拉增强剂 (A-ARI) 和组合布洛 (C-BUP) 被认为是TRD,但具有不同的风险概况,包括跌倒,体重增加和晚期动症 (TD).
- 转换为布洛 (S-BUP) 是另一种治疗选择,具有不同的比较有效性和安全性数据.
研究的目的:
- 进行风险效益分析,比较C-BUP和A-ARI与S-BUP用于TRD治疗.
- 评估这些策略对其相关风险的增强有效性,例如跌倒,体重增加和TD.
- 在TRD管理中为临床指南和共享决策提供信息.
主要方法:
- 采用健康状态过渡模型,在一年的治疗中模拟寿命质量调整寿命年 (QALYs).
- 该模型追踪了关键健康状况,包括抑郁症缓解,跌倒,体重增加和TD,按年龄和基线BMI分层.
- 来自VAST-D和OPTIMUM试验的数据,以及其他文献,为模型参数提供了信息. QALYs被转换为没有抑郁症的日均值 (DFD).
主要成果:
- 在18-64岁的成年人中,C-BUP表现出比S-BUP20.7 DFD的净益,表明症状缓解速度大约快3周.
- 对于老年人来说,C-BUP对S-BUP的好处部分被跌倒风险所抵消,特别是在85岁以上的人群中.
- 与S-BUP相比,A-ARI的益处较少 (8.0 DFD),由于TD和代谢损害,超重个体的益处减少到-22.8 DFD.
结论:
- 与S-BUP和A-ARI相比,组合布洛 (C-BUP) 在治疗85岁以下成年人的TRD中表现出更好的疗效和耐受性平衡.
- 在超重的成年人中,由于代谢不良影响,阿里皮普拉增量 (A-ARI) 最不喜欢.
- 这些发现支持C-BUP作为大多数TRD患者子组中首选的选择,指导临床实践和患者-提供者讨论.
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
761
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
761
01:26Psychosis: Goals of Pharmacotherapy
434
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
434
01:25Antidepressant Drugs: Overview
1.3K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.3K
01:28Drug Therapy
226
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
226
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
375
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
375
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
234
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
234